New perspectives on innovative drug discovery: An overview

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 3, 2010, Pages 450-471

  Pan, Si Yuan ^a   Pan, Shan ^b   Yu, Zhi Ling ^b   Ma, Dik Lung ^b   Chen, Si Bao ^c   Fong, Wang Fun ^b   Han, Yi Fan ^d   Ko, Kam Ming ^e  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^e HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; ARTEMISIN; ARTEMISININ; BERBERINE; CEPHALOSPORIN DERIVATIVE; CURCUMIN; DIGITALIS; ERYTHROPOIETIN; FLAVONOID; HEPATITIS B VACCINE; HUPERZINE A; INSULIN; MONOCLONAL ANTIBODY; MORPHINE; NUCLEIC ACID; PACLITAXEL; PENICILLIN G; POLYPHENOL DERIVATIVE; PROBIOTIC AGENT; QUININE; RECOMBINANT PROTEIN; RESERPINE; RESVERATROL; RIFAMYCIN DERIVATIVE; SULFANILAMIDE; TANNIN DERIVATIVE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOMEDICINE; CHINESE MEDICINE; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; ENTERITIS; GENE THERAPY; GENETIC DISORDER; GENETIC ENGINEERING; HUMAN; LIVER CARCINOMA; LIVER INJURY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICINAL PLANT; MULTIINFARCT DEMENTIA; MULTIPLE MYELOMA; NONHUMAN; PROMYELOCYTIC LEUKEMIA; SCHIZOPHRENIA; SKIN BRUISING; SNAKEBITE; SWELLING;

EID: 78650387939     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J39W2G     Document Type: Article

References (224)

1. Rishton GM. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am J Cardiol, 101:43D-49D, 2008.
2. Reichert JM, Milne CP. Public and private sector contributions to the discovery and development of "impact" drugs. Am J Ther, 9:543-555, 2002.
3. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov, 2:695-702, 2003.
4. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov, 8:959-968, 2009.
5. Grabowski H. Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures. Pharmacoeconomics, 22(2 Suppl 2):15-24, 2004.
6. Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ, 14:1-16, 2005.
7. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect, 22:119-125, 2009.
8. Reichert JM, Rochon SL, Zhang BD. Finding value in the U.S. Food and Drug Administration's Fast Track program. Drug News Perspect, 22:53-58, 2009.
9. Graul AI. Promoting, improving and accelerating the drug development and approval processes. Drug News Perspect, 21:36-43, 2008.
10. Graul AI, Revel L, Barrionuevo M, Cruces E, Rosa E, Verges C, Lupone B, Diaz N, Castaner R. The year's new drugs & biologics - 2008. Drug News Perspect, 22:7-29, 2009.
11. Pan SY, Chen SB, Dong HG, Yu ZL, Dong JC, Long ZX, Fong WF, Hanong WF, Han YF, Ko KM. New Perspectives on Chinese Herbal Medicine (Zhong-Yao) Research and Development. Evid Based Complement Alternat Med, doi:10.1093/ecam/neq056, 2010.
12. Maruyama Y, Wakamatsu A, Kawamura Y, Kimura K, Yamamoto J, Nishikawa T, Kisu Y, Sugano S, Goshima N, Isogai T, Nomura N. Human Gene and Protein Database (HGPD): a novel database presenting a large quantity of experiment-based results in human proteomics. Nucleic Acids Res, 37:D762-766, 2009.
13. Bentley DR. The Human Genome Project - anoverview. Med Res Rev, 20:189-196, 2000.
14. Heilker R, Wolff M, Tautermann CS, Bieler M. G-protein-coupled receptor-focused drug discovery using a target class platform approach. Drug Discov Today, 14:231-240, 2009.
15. Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, physical basis, and implications. J Med Chem, 51:2432-2438, 2008.
16. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res, 27:544-575, 2010.
17. Ellison D. Biopharmaceutical development and clinical manufacturing [updated 2008 Jun 9; cited 2010 Jan 25]. Available from: http://www.bionow.co.uk/uploads/documents/jun_08/bionow_1213884750_Dr_Derek_Ellison_Eden_Biodesig.pdf.
18. Chemier JA, Fowler ZL, Koffas MA, Leonard E. Trends in microbial synthesis of natural products and biofuels. Adv Enzymol Relat Areas Mol Biol, 76:151-117, 2009.
19. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol, 9:423-430, 2008.
20. Robak T. Treatment of chronic lymphoid leukemias with monoclonal antibodies: current place and perspectives. Drug Dev Res, 69:373-387, 2008.
21. Debinski W. Molecular targeting with recombinant cytotoxins for the treatment of brain tumors. Drug Dev Res, 69:407-414, 2008.
22. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med, 220:95-106, 2010.
23. Hollander PA, Cefalu WT, Mitnick M, Lawrence D, Rosenstock J. Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. Diabetes Technol Ther, 12:185-191, 2010.
24. Lau EM, Yozghatlian V, Kosky C, Moriarty C, Dentice R, Waugh R, Torzillo PJ, Bye PT. Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis. Chest, 136:277-281, 2009.
25. Ramjoué C. The transatlantic rift in genetically modified food policy. J Agr Environ Ethic, 20:419-436, 2007.
26. Kumar GB, Ganapathi TR, Revathi CJ, Srinivas L, Bapat VA. Expression of hepatitis B surface antigen in transgenic banana plants. Planta, 222:484-493, 2005.
27. Zhou H, Liu ZG, Sun ZW, Huang Y, Yu WY. Generation of stable cell lines by site-specific integration of transgenes into engineered Chinese hamster ovary strains using an FLP-FRT system. J Biotechnol, 147:122-129, 2010.
28. Jelkmann W. Erythropoiesis stimulating agents and techniques: a challenge for doping analysts. Curr Med Chem, 16:1236-1247, 2009.
29. Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC. Creation of a bacterial cell controlled by a chemically synthesized genome. Science, 329:52-56, 2010.
30. Tanaka T, Kuroki M, Hamada H, Kato K, Kinugasa T, Shibaguchi H, Zhao J, Kuroki M. Cancer-targeting gene therapy using tropism-modified adenovirus. Anticancer Res, 27:3679-3684, 2007.
31. Shirakawa T. Clinical trial design for adenoviral gene therapy products. Drug News Perspect, 22:140-145, 2009.
32. Blaese RM. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. Pediatr Res, 33(Suppl 1):S49-53, 1993.
33. Wasserfall CH, Herzog RW. Gene therapy approaches to induce tolerance in autoimmunity by reshaping the immune system. Curr Opin Investig Drugs, 10:1143-1150, 2009.
34. Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients. Drug News Perspect, 22:185-196, 2009.
35. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov, 9:363-366, 2010.
36. Borden EC, Raghavan D. Personalizing medicine for cancer: the next decade. Nat Rev Drug Discov, 9:343-344, 2010.
37. Pérez CM. Can ginkgo biloba combat diseases? P R Health Sci J, 28:66-74, 2009.
38. Leistner E, Drewke C. Ginkgo biloba and ginkgotoxin. J Nat Prod, 73:86-92, 2010.
39. Miller K, Neilan B, Sze DM. Development of Taxol and other endophyte produced anti-cancer agents. Recent Pat Anticancer Drug Discov, 3:14-19, 2008.
40. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther, 7:999-1013, 2009.
41. Hounsome N, Hounsome B, Tomos D, Edwards-Jones G. Plant metabolites and nutritional quality of vegetables. J Food Sci, 73:R48-65, 2008.
42. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat RevImmunol, 3:745-756, 2003.
43. Chan, SH, Lee HM, Yang F, Che CM, Wong CCL, Abagyan R, Leung CH, Ma DL. Structure-Based Discovery of Natural Product-Like TNF-α Inhibitors. Angew Chem Int Ed Engl, 49:2860-2863, 2010.
44. Pavlović RD, Lakusić B, Doslov-Kokorus Z, Kovacević N. Arbutin content and antioxidant activity of some ericaceae species. Pharmazie, 64:656-659, 2009.
45. Mothana RA, Gruenert R, Bednarski PJ, Lindequist U. Evaluation of the in vitro anticancer, antimicrobial and antioxidant activities of some Yemeni plants used in folk medicine. Pharmazie, 64:260-268, 2009.
46. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci, 12:46-78, 2009.
47. Bernhaus A, Ozsvar-Kozma M, Saiko P, Jaschke M, Lackner A, Grusch M, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest New Drugs, 27:393-401, 2009.
48. Sun AY, Wang Q, Simonyi A, Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol, 41:375-383, 2010.
49. Tunali-Akbay T, Sehirli O, Ercan F, Sener G. Resveratrol protects against methotrexate-induced hepatic injury in rats. J Pharm Pharm Sci, 13:303-310, 2010.
50. Gong S, Hao J, Xia Y, Liu X, Li J. Inhibitory effect of bionic fungicide 2-allylphenol on Botrytis cinerea (Pers. ex Fr.) in vitro. Pest Manag Sci, 65:1337-1343, 2009.
51. Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS. HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Front Biosci, 13:609-620, 2008.
52. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich), 12:40-46, 2010.
53. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L. chemistry, efficacy, safety, and uses. J Food Sci, 73:R14-19, 2008.
54. Li WF, Jiang JG, Chen J. Chinese medicine and its modernization demands. Arch Med Res, 39:246-251, 2008.
55. Deng ZL. Application of new techniques in the innovative research of Chinese herbal medicine. Chin Pharm, 16:58-59, 2007 (in Chinese).
56. Au WY, Kwong YL. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin, 296-304, 2008.
57. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. Oncologist, Suppl 2:29-32, 2001.
58. Dart RC. Medical toxicology. Williams & Wilkins, Philadelphia, pp1393-1401, 2004.
59. Liu J, Lu Y, Wu Q, Goyer RA, Waalkes MP. Mineral arsenicals in traditional medicines: Orpiment, realgar, and arsenolite. J Pharmacol Exp Ther, 326:363-368, 2008.
60. Hua HG, Wang JH, Q-in SD. Ancient and modern application of pi-Shuang. Chin J Chin Mater Med, 28:186-188, 2003 (in Chinese).
61. Thomas X, Troncy J. Arsenic: a beneficial therapeutic poison - a historical overview. Adler Mus Bull, 35:3-13, 2009.
62. Xu SN, Chen JP, Liu JP, Xia Y. Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis. J Chin Integr Med, 7:801-808, 2009 (in Chinese).
63. Leu L, Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm, 66:1913-1918, 2009.
64. Douer D, Tallman MS. Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. J Clin Oncol, 23:2396-2410, 2005.
65. Röllig C, Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev, 35:425-430, 2009.
66. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma, 7:192-198, 2006.
67. Li LH, Li HM. Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma-review. J Exp Hematol, 15:1335-1339, 2007 (in Chinese).
68. Li H, Xiong MM. Review of arsenic trioxide effect on human hepatocarcinoma. Cancer Res Clin, 18:712-714, 2006 (in Chinese).
69. Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev, 33:542-564, 2007.
70. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin, 27:1-26, 2006.
71. Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, Tang XC. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem Biol Interact, 175:396-402, 2008.
72. Guo B, Xu L, Wei Y, Liu C. Research advances of huperzia serrata (Thunb.) Trev. Chin J Chin Mater Med, 34:2018-2023, 2009 (in Chinese).
73. Desilets AR, Gickas JJ, Dunican KC. Role of huperzine a in the treatment of Alzheimer's disease. Ann Pharmacother, 43:514-518, 2009.
74. Zhang JC, Xing JH, Song YH, Wang ZM, Zhang HY. Recent advances in studies on herb biological of huperzia serrata(Thunb.)Trev. Chin Wild Plant Resources, 27:1-5, 2008 (in Chinese).
75. Fu Y, Li S, Zu Y, Yang G, Yang Z, Luo M, Jiang S, Wink M, Efferth T. Medicinal chemistry of paclitaxel and its analogues. Curr Med Chem, 16:3966-3985, 2009.
76. Li B, Zhu WL, Chen KX. Advances in the study of berberine and its derivatives. Acta Pharm Sin, 43:773-787, 2008 (in Chinese).
77. Carmargo LM, de Oliveira S, Basano S, Garcia CR. Antimalarials and the fight against malaria in Brazil. Ther Clin Risk Manag, 5:311-317, 2009.
78. Liu GT. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem, 5:29-43, 2009.
79. Liu GT. From the study of Fructus schizandrae to the discovery of biphenyl dimethyl-dicarboxylate. Acta pharm Sin, 18:714-720, 1983 (in Chinese).
80. Tang Y, Hu W, Li Y, Zhang CZ. Synthesis of metabolites of bicyclol. Acta pharm Sin, 42:1054-1057, 2007 (in Chinese).
81. Chang JB, Wang Q, Li YF. Synthesis and biological activity of Wuweizisu C and analogs. Curr Top Med Chem, 9:1660-1675, 2009.
82. Pan SY, Yang R, Dong H, Yu ZL, Ko KM. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol, 552:170-175, 2006.
83. Pan SY, Dong H, Yu ZL, Zhao XY, Xiang CJ, Wang H, Fong WF, Ko KM. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol, 59:1657-1662, 2007.
84. Pan SY, Yu ZL, Dong H, Xiang CJ, Fong WF, Ko KM. Ethanol Extract of Fructus Schisandrae Decreases Hepatic Triglyceride Level in Mice Fed with a High Fat/Cholesterol Diet, with Attention to Acute Toxicity. Evid Based Complement Alternat Med, doi:10.1093/ecam/nep070, 2009.
85. Pan SY, Dong H, Zhao XY, Xiang CJ, Fang HY, Fong WF, Yu ZL, Ko KM. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol, 60:399-403, 2008.
86. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des, 15:2087-2094, 2009.
87. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem, 17:190-197, 2010.
88. Sikora E, Bielak-Zmijewska A, Mosieniak G, Piwocka K. The promise of slow down ageing may come from curcumin. Curr Pharm Des, 16:884-892, 2010.
89. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science, 325:1089-1093, 2009.
90. Petrosillo N, Capone A, Di Bella S, Taglietti F. Management of antibiotic resistance in the intensive care unit setting. Expert Rev Anti Infect Ther, 8:289-302, 2010.
91. Newman DJ, Cragg GM. Microbial antitumor drugs: natural products of microbial origin as anticancer agents. Curr Opin Investig Drugs, 10:1280-1296, 2009.
92. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther, 35:139-151, 2010.
93. Corbetta G, Ponticelli C. Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale. Transplant Proc, 42:1303-1307, 2010.
94. Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine, 25:3752-3762, 2007.
95. Williams NT. Probiotics. Am J Health Syst Pharm, 67:449-458, 2010.
96. Liong MT, Shah N P. Effects of a Lactobacillus casei synbiotic on serum lipoprotein, intestinal microflora, and organic acids in rats. J Dairy Sci, 89:1390-1399, 2006.
97. Linsalata M, Cavallini A, Messa C, Orlando A, Refolo MG, Russo F. Lactobacillus rhamnosus GG influences polyamine metabolism in HGC-27 gastric cancer cell line: a strategy toward nutritional approach to chemoprevention of gastric cance. Curr Pharm Des, 16:847-853, 2010.
98. Galdeano CM, de Moreno de Le Blanc A, Vinderola G, Bonet MEB, Perdigon G. Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin Vaccine Immunol, 14:485-492, 2007.
99. Russell WR, Scobbie L, Chesson A, Richardson AJ, Stewart CS, Duncan SH, Drew JE, Duthie GG. Anti-inflammatory implications of the microbial transformation of dietary phenolic compounds. Nutr Cancer, 60:636-642, 2008.
100. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, Kozáková H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D, Reháková Z, Sinkora J, Hofman J, Drastich P, Kokesová A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett, 93:97-108, 2004.
101. Kinross J.M, von Roon AC, Holmes E, Darzi A, Nicholson JK. The human gut microbiome: implications for future health care. Curr Gastroenterol Rep, 10:396-403, 2008.
102. Possemiers S, Grootaert C, Vermeiren J, Gross G, Marzorati M, Verstraete W, Van de Wiele T. The intestinal environment in health and disease - recent insights on the potential of intestinal bacteria to influence human health. Curr Pharm Des, 15:2051-2065, 2009.
103. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol, 26:5-11, 2010.
104. Othman M, Agüero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol, 24:11-16, 2008.
105. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep, 7:688-693, 2006.
106. Chhibber S, Kaur S, Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol, 57:1508-1513, 2008.
107. Williams R. Review article: bacterial flora and pathogenesis in hepatic encephalopathy. Aliment Pharmacol Ther, 25 (Suppl 1):17-22, 2007.
108. Cooper EL. Drug discovery, CAM and natural products. Evid Based Complement Altern Med, 1:215-217, 2004.
109. Pallela R, Na-Young Y, Kim SK. Anti-photoaging and photoprotective compounds derived from marine organisms. Mar Drugs, 8:1189-1202, 2010.
110. Villa FA, Gerwick L. Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders. Immunopharmacol Immunotoxicol, 32:228-237, 2010.
111. Chang Z, Sitachitta N, Rossi JV, Roberts MA, Flatt PM, Jia J, Sherman DH, Gerwick WH. Biosynthetic pathway and gene cluster analysis of curacin A, an antitubulin natural product from the tropical marine cyanobacterium Lyngbya majuscula. J Nat Prod, 67:1356-1367, 2004.
112. Wijesekara I, Kim SK. Angiotensin-I-converting enzyme (ACE) inhibitors from marine resources: prospects in the pharmaceutical industry. Mar Drugs, 8:1080-1093, 2010.
113. Mincer TJ, Jensen PR, Kauffman CA, Fenical W. Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments. Appl Environ Microbiol, 68:5005-5011, 2002.
114. Fenical W, Jensen PR, Palladino MA, Lam KS, Lloyd GK, Potts BC. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem, 17:2175-2180, 2009.
115. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer, 95:961-965, 2006.
116. Singh R, Sharma M, Joshi P, Rawat DS. Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem, 8:603-617, 2008.
117. Adrian TE. Novel marine-derived anti-canceragents. Curr Pharm Des, 13:3417-3426, 2007.
118. Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep, 24:31-86, 2007.
119. Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep, 25:35-94, 2008.
120. Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep, 26:170-244, 2009.
121. Schwartsmann G, Da Rocha AB, Mattei J, Lopes R. Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs, 12:1367-1383, 2003.
122. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today, 8:536-544, 2003.
123. Williams PG. Panning for chemical gold: marine bacteria as a source of new therapeutics. Trends Biotechnol, 27:45-52, 2009.
124. Freile-Pelegrin Y, Robledo D, Chan-Bacab MJ, Ortega-Morales BO. Antileishmanial properties of tropical marine algae extracts. Fitoterapia, 79:374-377, 2008.
125. Martinez A. Marine-derived drugs in neurology. Curr Opin Investig Drugs, 8:525-530, 2007.
126. Zhang W, Guo YW, Gu Y. Secondary metabolites from the South China Sea invertebrates: chemistry and biological activity. Curr Med Chem, 13:2041-2090, 2006.
127. Zhang W, Xue S, Zhao Q, Zhang X, Li J, Jin M, Yu X, Yuan Q. Biopotentials of marine sponges from China oceans: past and future. Biomol Eng, 20:413-419, 2003.
128. Fenical W. New pharmaceuticals from marine organisms. Trends Biotechnol, 15:339-341, 1997.
129. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov, 8:69-85, 2009.
130. Burzynski SR. Antineoplastons: history of the research (I). Drugs Exp Clin Res, 12(suppl 1):1-9, 1986.
131. Lin WC, Wu YW, Lai TY, Liau MC. Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am J Chin Med, 29:91-99, 2001.
132. Huang J, Yang M, Liu H, Jin J. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin, 29:951-964, 2008.
133. Huang J, Yang M, Liu H, Jin J. CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner. Food Chem Toxicol, 47:40-49, 2009.
134. al-Harbi MM, Qureshi S, Ahmed MM, Raza M, Baig MZ, Shah AH. Effect of camel urine on the cytological and biochemical changes induced by cyclophosphamide in mice. J thnopharmacol, 52:129-137, 1996.
135. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med, 9:145-152, 2010.
136. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, MacDonald KS, Ngugi EN, Plummer FA. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet, 348:1347-1351, 1996.
137. Gurwitz D. Malaria drugs: clues from malaria resistance genetics. Drug Dev Res, 71:1-3, 2010.
138. Ma H, Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discov Today, 13:402-408, 2008.
139. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov, 6:287-293, 2007.
140. Drews J, Ryser S. The role of innovation in drug development. Nat Biotechnol, 15:1318-1319, 1997.
141. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today, 10:1607-1610, 2005.
142. Dunkel M, Günther S, Ahmed J, Wittig B, Preissner R. SuperPred: drug classification and target prediction. Nucleic Acids Res, 36:W55-59, 2008.
143. MacDonald L, Foster BC, Akhtar H. Food and therapeutic product interactions - a therapeutic perspective. J Pharm Pharm Sci, 12:367-377, 2009.
144. Györéné KG, Varga A, Lugasi A. A comparison of chemical composition and nutritional value of organically and conventionally grown plant derived foods. Orv Hetil, 147:2081-2090, 2006 (in Hungarian).
145. Celik H, Arinç E. Evaluation of the protective effects of quercetin, rutin, naringenin, resveratrol and trolox against idarubicin-induced DNA damage. J Pharm Pharm Sci, 13:231-241, 2010.
146. Calabrese V, Cornelius C, Trovato A, Cavallaro M, Mancuso C, Di Rienzo L, Condorelli D, De Lorenzo A, Calabrese EJ. The hormetic role of dietary antioxidants in free radical-related diseases. Curr Pharm Des, 6:877-883, 2010.
147. Bastianetto S, Krantic S, Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini Rev Med Chem, 8:429-435, 2008.
148. Song WO, Chun OK, Hwang I, Shin HS, Kim BG, Kim KS, Lee SY, Shin D, Lee SG. Soy isoflavones as safe functional ingredients. J Med Food, 10:571-580, 2007.
149. Moţa M, Gârgavu S, Popa S, Schiopu S, Panduru NM, Moţa E. Soya-the medicine food product. Rom J Intern Med, 45:113-121, 2007.
150. Molinié B, Georgel P. Genetic and epigenetic regulations of prostate cancer by genistein. Drug News Perspect, 22:247-254, 2009.
151. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem, 9:31-59, 2009.
152. Sen CK, Khanna S, Roy S. Tocotrienols in health and disease: the other half of the natural vitamin E family. Mol Aspects Med, 28:692-728, 2007.
153. Sen CK, Khanna S, Rink C, Roy S. Tocotrienols: the emerging face of natural vitamin E. Vitam Horm, 76:203-261, 2007.
154. Hekimoglu A, Kurcer Z, Aral F, Baba F, Sahna E, Atessahin A. Lycopene, an antioxidant carotenoid, attenuates testicular injury caused by ischemia/reperfusion in rats. Tohoku J Exp Med, 218:141-147, 2009.
155. Parvin R, Akhter N. Protective effect of tomato against adrenaline-induced myocardial infarction in rats. Bangladesh Med Res Counc Bull, 34:104-108, 2008.
156. Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J, 12:87-97, 2010.
157. Nakamura Y, Miyoshi N. Electrophiles in foods: the current status of isothiocyanates and their chemical biology. Biosci Biotechnol Biochem, 74:242-255, 2010.
158. Takahashi N, Goto T, Taimatsu A, Egawa K, Katoh S, Kusudo T, Sakamoto T, Ohyane C, Lee JY, Kim YI, Uemura T, Hirai S, Kawada T. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation. Biochem Biophys Res Commun, 390:1372-1376, 2009.
159. Bastianetto S, Krantic S, Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini Rev Med Chem, 8:429-435, 2008.
160. Erdmann K, Cheung BW, Schröder H. The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. J Nutr Biochem, 19:643-654, 2008.
161. Aihara K, Ishii H, Yoshida M. Casein-derived tripeptide, Val-Pro-Pro (VPP), modulates monocyte adhesion to vascular endothelium. J Atheroscler Thromb, 16:594-603, 2009.
162. Aluko RE. Technology for the production and utilization of food protein-derived anti-hypertensive peptides: a review. Recent Pat Biotechnol, 1:260-267, 2007.
163. Guang C, Phillips RD. Plant food-derived Angiotensin I converting enzyme inhibitory peptides. J Agric Food Chem, 57:5113-5120, 2009.
164. Ashrafian H, Darzi A, Athanasiou T. Autobionics: a new paradigm in regenerative medicine and surgery. Regen Med, 5:279-288, 2010.
165. Green DW. Tissue bionics: examples in biomimetic tissue engineering. Biomed Mater, doi: 10.1088/1748-6041/3/3/034010, 2008.
166. Green BA, Yu RJ, Van Scott EJ. Clinical and cosmeceutical uses of hydroxyacids. Clin Dermatol, 27:495-501, 2009.
167. Hervé JC. Therapeutic potential of peptide motifs - part III. Curr Pharm Des, 16:1021-1023, 2010.
168. Conlon JM. Reflections on a systematic nomenclature for antimicrobial peptides from the skins of frogs of the family Ranidae. Peptides, 29:1815-1819, 2008.
169. Conlon JM, Kolodziejek J, Nowotny N. Antmicrobial peptides from ranid frogs: taxonomic and phylogenetic markers and a potential source of new therapeutic agents. Biochim Biophys Acta, 1696:1-14, 2004.
170. Barra D, Simmaco M. Amphibian skin: a promising resource for antimicrobial peptides. Trends Biotechnol, 13:205-209, 1995.
171. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res, 30:505-515, 2005.
172. Pini A, Falciani C, Bracci L. Branched peptides as therapeutics. Curr Protein Pept Sci, 9:468-477, 2008.
173. Takeuchi O, Akira S. RIG-I-like antiviral protein in flies. Nat Immunol, 9:1327-1328, 2008.
174. Deddouche S, Matt N, Budd A, Mueller S, Kemp C, Galiana-Arnoux D, Dostert C, Antoniewski C, Hoffmann JA, Imler JL. The DExD/H-box helicase Dicer-2 mediates the induction of antiviral activity in drosophila. Nat Immunol, 9:1425-1432, 2008.
175. Carroll FI. Epibatidine structure-activity relationships. Bioorg Med Chem Lett, 14:1889-1896, 2004.
176. Nemec K, Schubert-Zsilavecz M. From teprotide to captopril. Rational design of ACE inhibitors. Pharm Unserer Zeit, 32:11-16, 2003 (in German).
177. Tabarrok A. From off-label prescribing towards a new FDA. Med Hypotheses, 72:11-13, 2009.
178. Chang SP, Tsai HH, Chen WY, Lee WR, Chen PL, Tsai TH. The wrinkles soothing effect on the middle and lower face by intradermal injection of botulinum toxin type A. Int J Dermatol, 47:1287-1294, 2008.
179. Aguggia M. Treating headaches with botulinum toxin. Neurol Sci, 29 (Suppl 1):S137-139, 2008.
180. Millán-Guerrero RO, Isais-Millán S, Barreto-Vizcaíno S, Rivera-Castaño L, Rios-Madariaga C. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study. Eur J Neurol, 16:88-94, 2009.
181. Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi X, Ichinose S, Yamamoto N, Yamaoka S. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect, 10:471-480, 2008.
182. Gilbert C, Bergeron M, Méthot S, Giguère JF, Tremblay MJ. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol, 18:474-489, 2005.
183. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun, 323:264-268, 2004.
184. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J, doi:10.1186/1743-422X-2-69, 2005.
185. Gakhar G, Ohira T, Shi A, Hua DH, Nguyen TA. Antitumor effect of substituted quinolines in breast cancer cells. Drug Dev Res, 69:526-534, 2008.
186. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med, 356:2131-2142, 2007.
187. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology, 134:21-28, 2008.
188. Jurcic JG, Soignet SL, Maslak AP. Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep, 9:337-344, 2007.
189. Basu M, Duckett JR. Detrusor overactivity successfully treated with duloxetine. J Obstet Gynaecol, 27:438-440, 2007.
190. Wang R, Li C, Song D, Zhao G, Zhao L, Jing Y. Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition. Cancer Res, 67:7856-7864, 2007.
191. Durk HA. Maintenance therapy for multiple myeloma with particular emphasis on thalidomide. Onkologie, 29:582-590, 2006.
192. Villahermosa LG, Fajardo TT Jr, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide fortreatment of erythema nodosum leprosum. Am J Trop Med Hyg, 72:518-526, 2005.
193. Orsucci D, Calsolaro V, Mancuso M, Siciliano G. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets, 8:222-231, 2009.
194. Noble W, Garwood CJ, Hanger DP. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion, 3:78-83, 2009.
195. Nzila A, Okombo J, Becker RP, Chilengi R, Lang T, Niehues T. Anticancer agents against malaria: time to revisit? Trends Parasitol, 26:125-129, 2010.
196. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, Majori G, Severini C. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. FEBS Lett, 582:844-847, 2008.
197. Rishton GM. Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations. Med Chem, 1:519-527, 2005.
198. Kuhlmann J. The applications of biomarkers inearly clinical drug development to improve decision-making processes. Ernst Schering Res Found Workshop, 59:29-45, 2007.
199. Westerhoff HV, Mosekilde E, Noe CR, Clemensen AM. Integrating systems approaches into pharmaceutical sciences. Eur J Pharm Sci, 35:1-4, 2008.
200. Rescigno A. The two faces of pharmacokinetics. J Pharm Pharm Sci, 13:38-42, 2010.
201. Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Carl K, Catalano J, Charlab R, Close S, Cornu-Artis C, Essioux L, Fornace AJ Jr, Hinman L, Hong H, Hunt I, Jacobson-Kram D, Jawaid A, Laurie D, Lesko L, Li HH, Lindpaintner K, Mayne J, Morrow P, Papaluca-Amati M, Robison TW, Roth J, Schuppe-Koistinen I, Shi L, Spleiss O, Tong W, Truter SL, Vonderscher J, Westelinck A, Zhang L, Zineh I. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov, 9:435-445, 2010.
202. Janiszewski JS, Liston TE, Cole MJ. Perspectives on bioanalytical mass spectrometry and automation in drug discovery. Curr Drug Metab, 9:986-994, 2008.
203. Peterson ML, Hickey MB, Zaworotko MJ, Almarsson O. Expanding the scope of crystal form evaluation in pharmaceutical science. J Pharm Pharm Sci, 9:317-326, 2006.
204. Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drugdevelopment? Drugs R D, 9:351-368, 2008.
205. Clark M, Meshkat S, Talbot G, Konteatis Z, Ludington J, Zou J, Freedman SJ, Wiseman JS. Developing technologies in biodefense research: computational drug design. Drug Dev Res, 70:279-287, 2009.
206. Michel J, Essex JW. Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. J Comput Aided Mol Des, May 28 10.1007/s10822-010-9363-3, 2010.
207. Custer LL, Sweder KS. The role of genetic toxicology in drug discovery and optimization. Curr Drug Metab, 9:978-985, 2008.
208. Eglen RM, Reisine T. Photoproteins: important new tools in drug discovery. Assay Drug Dev Technol, 6:659-671, 2008.
209. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem, 9(Suppl 1):S7, 2008.
210. Ehrman TM, Barlow DJ, Hylands PJ. Phytochemical informatics and virtual screening of herbs used in Chinese medicine. Curr Pharm Des, 16:1785-1798, 2010.
211. Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150:344-347.
212. Shi J, Yang JW, Kuang JX. Thoughts on the Chinese herbal medicine granulaes. Acta Acad Med Zunyi, 32:557-586, 2003 (in Chinese).
213. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov, 9:203-214, 2010.
214. Jain D, Pathak D, Pathak K. Pharmaceutical product development technologies based on the biopharmaceutical classification system. Pharmazie, 64:483-490, 2009.
215. Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J, 11:155-166, 2009.
216. Prakash C, Sharma R, Gleave M, Nedderman A. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr Drug Metab, 9:952-964, 2008.
217. Ryan TP, Stevens JL, Thomas CE. Strategic applications of toxicogenomics in early drug discovery. Curr Opin Pharmacol, 8:654-660, 2008.
218. Watson P. Live cell imaging for target and drug discovery. Drug News Perspect, 22:69-79, 2009.
219. Greene N, Naven R. Early toxicity screening strategies. Curr Opin Drug Discov Devel, 12:90-97, 2009.
220. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod, 66:1022-1037, 2003.
221. Grabley S, Thiericke R. Bioactive agents from natural sources: trends in discovery and application. Adv Biochem Eng Biotechnol, 64:101-154, 1999.
222. Molinari G. Natural products in drug discovery: present status and perspectives. Adv Exp Med Biol, 655:13-27, 2009.
223. Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J, 8:E239-253, 2006.
224. Vuorelaa P, Leinonenb M, Saikkuc P, Tammelaa P, Rauhad JP, Wennberge T, Vuorela H. Natural products in the process of finding new drug candidates. Curr Med Chem, 11:1375-1389, 2004.